A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions

Healthy Participants

Interventions

DRUG

Povorcitinib

Povorcitinib will be administered at protocol defined dose.

DRUG

Placebo

Placebo will be administered at protocol defined dose.

DRUG

Moxifloxacin

Moxifloxacin will be administered at protocol defined dose.

Trial Locations (1)

Celerion Clinical Research Unit, Tempe